From Issuer Pays to Polluter Pays: Unearthing Piramal Pharma’s Credit Ratings
From Issuer Pays to Polluter Pays: Unearthing Piramal Pharma’s Credit Ratings Posted on 16th January, 2026 (GMT 01:48 hrs) ABSTRACT Piramal Pharma Limited (PPL), demerged from Piramal Enterprises in 2022, enjoys high investment-grade credit ratings (e.g., CARE AA; Stable upgraded July 2025) under the issuer-pays model, which critics claim manufactures trust to enable cheap borrowing despite severe financial strain—Q2 FY26 revenue down ~9% to ₹2,044 crore, EBITDA crashed 44%, net loss ₹99 crore, high leverage (~3x net debt-to-EBITDA), weak interest coverage, and share price falling ~19% from ₹204 (July 2025) to ~₹166 (mid-January 2026). This rating resilience contrasts sharply with the alleged “Digwal massacre” at its Telangana plant: repeated effluent dumping (comprehensively reported by 2018) contaminating water/soil, devastating farmland, and linked to spikes in kidney failures, respiratory issues, and cancers among villagers; despite NGT’s ₹8.3 crore polluter-pays fine (2...